Patheon IncTSX: PTI

Patheon Announces New Bank Financing Arrangements

· Issued by Patheon Inc via CNW
TORONTO, Nov. 3 /CNW/ - Patheon Inc. (TSX: PTI) today announced that it
will be proceeding to put in place new credit facilities in the aggregate
amount of $290 million to refinance existing debt of Patheon Inc. and its U.S.
subsidiaries including its subsidiaries in Puerto Rico. The new facilities
will replace (i) existing credit facilities that are available to the
Company's North American operations including those that were established at
the time of the acquisition of MOVA Pharmaceutical Corporation in December
2004, and (ii) debt of MOVA Pharmaceutical Corporation and its affiliates in
Puerto Rico that was assumed at the time of the acquisition by Patheon. (All
amounts are in U.S. dollars unless otherwise indicated.)
The new credit facilities will comprise a revolving facility in the
amount of $75 million and two term loans in the aggregate amount of        
$215 million. The term loans will consist of a five-year term loan in the
amount of $65 million and a six-year term loan in the amount of $150 million.
The new facilities will be secured by the North American assets of Patheon and
its subsidiaries, including those in Puerto Rico.
The Company has engaged Royal Bank of Canada and RBC Capital Markets as
Lead Arranger to syndicate these new credit facilities to a group of financial
institutions in Canada and the United States. The refinancing is expected to
close in December 2005.

Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug
development and manufacturing services to the international pharmaceutical
industry. Patheon operates a network of 14 facilities in the United States,
Canada and Europe, employing more than 5,900 people and serving a client base
of 180 pharmaceutical and biotechnology companies.

This news release contains forward-looking statements with respect to
Patheon, including its business operations and strategy and financial
performance and condition. Although management believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties. Actual results may differ materially from
those expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from expectations include, but
are not limited to, currency fluctuations, the level of outsourcing services
required by the pharmaceutical companies (and in particular our clients), the
impact of changes in pharmaceutical development and manufacturing regulations
and general economic and market factors (including inflation and changes in
laws) and other factors discussed in materials filed with applicable
securities regulatory authorities from time to time.

%SEDAR: 00001700E

Patheon Inc on 6ix

Earlier from Patheon

Later from Patheon

All Patheon news releases